Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Single-agent Tesetaxel in Chemotherapy-naive Patients Who Have Progressive, Castration-resistant Prostate Cancer

NCT01296243 is registered in ClinicalTrials.gov with Genta Incorporated as lead sponsor.

NCT NCT01296243
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01296243 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Single-agent Tesetaxel in Chemotherapy-naive Patients Who Have Progressive, Castration-resistant Prostate Cancer
Lead sponsor
Genta Incorporated
Phase
Phase 2
Overall status
Unknown status
Start date
February 28, 2011
Completion date
February 28, 2015
Enrollment
57 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer